Green Cross Lab Cell Corporation (144510) - Total Liabilities

Latest as of September 2025: ₩134.23 Billion KRW ≈ $90.97 Million USD

Based on the latest financial reports, Green Cross Lab Cell Corporation (144510) has total liabilities worth ₩134.23 Billion KRW (≈ $90.97 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Green Cross Lab Cell Corporation (144510) equity growth momentum to track the company's year-over-year net asset growth rate.

Green Cross Lab Cell Corporation - Total Liabilities Trend (2015–2024)

This chart illustrates how Green Cross Lab Cell Corporation's total liabilities have evolved over time, based on quarterly financial data. See Green Cross Lab Cell Corporation free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Green Cross Lab Cell Corporation Competitors by Total Liabilities

The table below lists competitors of Green Cross Lab Cell Corporation ranked by their total liabilities.

Company Country Total Liabilities
Seven West Media Ltd
AU:SWM
Australia AU$1.15 Billion
Renaissance Global Limited
NSE:RGL
India Rs8.69 Billion
Sang-A Frontec Co.Ltd
KQ:089980
Korea ₩171.13 Billion
China Automotive Systems Inc
NASDAQ:CAAS
USA $551.00 Million
Paik Kwang Ind
KO:001340
Korea ₩382.49 Billion
Journey Medical Corp
NASDAQ:DERM
USA $62.74 Million
Globe Union Industrial Corp
TW:9934
Taiwan NT$9.81 Billion
Red Planet Indonesia Tbk
JK:PSKT
Indonesia Rp59.30 Billion

Liability Composition Analysis (2015–2024)

This chart breaks down Green Cross Lab Cell Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Green Cross Lab Cell Corporation market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.60 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.31 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.24 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Green Cross Lab Cell Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Green Cross Lab Cell Corporation (2015–2024)

The table below shows the annual total liabilities of Green Cross Lab Cell Corporation from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩120.56 Billion
≈ $81.70 Million
-2.53%
2023-12-31 ₩123.69 Billion
≈ $83.82 Million
-10.42%
2022-12-31 ₩138.07 Billion
≈ $93.57 Million
+2.60%
2021-12-31 ₩134.57 Billion
≈ $91.20 Million
+360.97%
2020-12-31 ₩29.19 Billion
≈ $19.78 Million
+21.56%
2019-12-31 ₩24.02 Billion
≈ $16.27 Million
+151.56%
2018-12-31 ₩9.55 Billion
≈ $6.47 Million
+35.76%
2017-12-31 ₩7.03 Billion
≈ $4.77 Million
+9.59%
2016-12-31 ₩6.42 Billion
≈ $4.35 Million
-18.81%
2015-12-31 ₩7.90 Billion
≈ $5.36 Million
--

About Green Cross Lab Cell Corporation

KQ:144510 Korea Diagnostics & Research
Market Cap
$136.05 Million
₩200.76 Billion KRW
Market Cap Rank
#17958 Global
#733 in Korea
Share Price
₩13360.00
Change (1 day)
+5.11%
52-Week Range
₩12710.00 - ₩27500.00
All Time High
₩126167.70
About

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in Nove… Read more